The OCUL Paradox: Analysts Bullish But Forecast -5.22% Fall
December 24, 2020 at 10:52 AM EST
Analyst ratings can sometimes be complicated, and we here at ETF Channel have noticed a bit of a paradox with Ocular Therapeutix Inc (OCUL). The average 12-month price target for OCUL — averaging the work of 6 analysts — reveals an average price target of $20.83/share..